Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction.
Patients receiving the oral glycoprotein IIb-IIIa inhibitor orbofiban in the OPUS -TIMI 16 trial had a paradoxical increase in platelet reactivity with respect to both fibrinogen binding and alpha-granule degranulation, suggesting a mechanism for the lack of efficacy of orbofiban in the trial. Thus, sensitive assays of platelet reactivity may be helpful in the design of further clinical studies and implementation of antiplatelet therapy in patients.
Holmes
M B
MB
Department of Medicine, The University of Vermont College of Medicine, Burlington 05401, USA. michael.holmes@vtmednet.org
Sobel
B E
BE
Cannon
C P
CP
Schneider
D J
DJ
D000208:Acute Disease; D000284:Administration, Oral; D000409:Alanine / Q000008:administration & dosage / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology*; D003328:Coronary Thrombosis / Q000097:blood* / Q000188:drug therapy; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011759:Pyrrolidines / Q000008:administration & dosage / Q000627:therapeutic use*; D012008:Recurrence; D015912:Thrombolytic Therapy; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011759:Pyrrolidines; D005340:Fibrinogen; C120234:orbofiban; D000409:Alanine